Hillhouse, Temasek-backed COVID vaccine developer Clover files for HK IPO

Photo: National Cancer Institute/Unsplash

Clover Biopharmaceuticals, a Chinese pre-revenue, clinical-stage biotech firm developing COVID-19 and other novel vaccines, has filed for an initial public offering (IPO) in Hong Kong.

Its prospectus filed with the Hong Kong stock exchange on April 23 is highly redacted. The firm is yet to reveal more detailed information, such as its offering price and targeted IPO size.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter